바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

16오늘 방문

568누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

AntibodyBHotBeiGeneVedotin, Tislelizumab, and …Phase 1

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#인기#항체+5

효능 ORR 68.3%임상시험 105상태 RECRUITING

ADCBHotBiologicK-Group, Beta, Inc., a wholly o…atPhase 3

Gemcitabine Hydrochloride (Gemcitabine Hydrochloride)

Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 50%임상시험 105상태 RECRUITING

ADCBHotBiologicPharmacyclics LLC.Phase 3

Ibrutinib (Ibrutinib)

Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 93.9%임상시험 105상태 ACTIVE

AntibodyBHotMerck KGaAvedotin (EV) was the most c…Phase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#인기#항체+5

효능 ORR 74%임상시험 105상태 ACTIVE

ADCCHotBiologicHoffmann-La RochePhase 2

Luteinizing Hormone-Releasing Hormone (LHRH, Luteinizing Hormone-Releasing Hormone, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 31%임상시험 104상태 RECRUITING

ADCBHotBiologicNovartis PharmaceuticalsApproved

Prednisolone (Prednisolone)

Healthy · Solid Tumor

#SolidTumor#ADC#Approved#인기#항체약물접합체+3

효능 ORR 47%임상시험 102상태 RECRUITING

AntibodyCHotXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#인기#항체+5

임상시험 101상태 RECRUITING

AntibodyCHotRochederuxtecan plus fluoropyrim…Phase 2

trastuzumab (Herceptin, FLOT, 5-FU, leucovorin, docetaxel, oxaliplatin, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#인기#항체+5

효능 ORR 61%임상시험 100상태 ACTIVE

AntibodyCMerckPhase 2

pembrolizumab (Keytruda, KEYTRUDA(R, Pembrolizumab (KEYTRUDA(R)))

Metastatic HPV-16 Positive Squamous Cell Anal Cancer · Metastatic HPV-16 Positive Squamous Cell

#MetastaticHPV-16PositiveSquamous#Antibody#Phase2#인기#항체+3

효능 ORR 78.3%임상시험 99상태 DISCONTINUED

AntibodyBNovartisApproved

AIN457 (Secukinumab, Secukinumab (AIN457))

Psoriatic Arthritis · Moderate to Severe Plaque-type Psoriasis

#ModeratetoSeverePlaque-typePsori#Antibody#Approved#인기#항체+4

효능 ORR 53%임상시험 98상태 ACTIVE

AntibodySRocheDM1 via butelase-1 with ABD…Phase 3

trastuzumab (Herceptin)

Breast Cancer · Healthy

#Healthy#Antibody#Phase3#인기#항체+5

효능 ORR 91.2%임상시험 97상태 ACTIVE

ADCCBiologicEMD SeronoSN-38 for the treatment of …Phase 2

TMZ (Temozolomide, Temozolomide (TMZ))

Childhood Cancer; Childhood Solid Tumor · Advanced Solid Malignancies

#AdvancedSolidMalignancies#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 40%임상시험 97상태 RECRUITING

AntibodyCPENG YUANPhase 2

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#인기#항체+5

임상시험 97상태 RECRUITING

CGTABiologicAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5

효능 ORR 77.3%임상시험 96상태 RECRUITING

AntibodyCBeiGeneVedotin, Tislelizumab, and …Phase 2

Tislelizumab (Tislelizumab)

Locally Recurrent Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#인기#항체+5

효능 ORR 37.1%임상시험 96상태 RECRUITING

AntibodyCInnoventvedotin (an HER2-targeted a…Phase 3

Sintilimab (Sintilimab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5

임상시험 95상태 RECRUITING

AntibodyBNovartisPhase 3

secukinumab (AIN457, AIN457 (secukinumab))

Asthma · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Phase3#인기#항체+4

효능 ORR 53%임상시험 95상태 ACTIVE

ADCBBiologicGileadPhase 2

SG (Sacituzumab Govitecan-hziy, Sacituzumab Govitecan-hziy (SG))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase2#인기#항체약물접합체+4

효능 ORR 34.3%임상시험 94상태 RECRUITING

AntibodyCJunshi Biosciencesvedotin (EV) in combination…Phase 3

Toripalimab (Toripalimab)

Metastatic Colorectal Cancer; Liver Metastases · Gastric Cancer

#GastricCancer#Antibody#Phase3#인기#항체+5

임상시험 93상태 RECRUITING

ADCABiologicAstraZenecaPhase 2

5-FU (Fluorouracil, Fluorouracil (5-FU))

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 63.5%임상시험 93상태 RECRUITING

ADCABiologicAmgenPhase 3

Pegfilgrastim (Pegfilgrastim)

Cancer; Colon Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase3#인기#항체약물접합체+4

효능 ORR 56.7%임상시험 93상태 RECRUITING

ADCCBiologicJiangsu Simcere Pharmaceutical …Phase 3

Palbociclib (Palbociclib)

Head and Neck Squamous Cell Carcinoma · FRα

#FR#ADC#Phase3#인기#항체약물접합체+3

효능 ORR 79.5%임상시험 92상태 DISCONTINUED

ADCABiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan (T-DXd) monotherapy)

Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 79.7%임상시험 91상태 RECRUITING

AntibodyARochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Triple-Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+4

효능 ORR 76.7%임상시험 90상태 ACTIVE

ADCBBiologicBayerPhase 3

Regorafenib (Regorafenib)

Metastatic Colorectal Cancer · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase3#인기#항체약물접합체+3

효능 ORR 54%임상시험 90상태 RECRUITING

4 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 16 / 568

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Gemcitabine Hydrochloride (Gemcitabine Hydrochloride)

Ibrutinib (Ibrutinib)

Avelumab (Avelumab)

Luteinizing Hormone-Releasing Hormone (LHRH, Luteinizing Hormone-Releasing Hormone, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists)

Prednisolone (Prednisolone)

AK104 (Cadonilimab, Cadonilimab (AK104))

trastuzumab (Herceptin, FLOT, 5-FU, leucovorin, docetaxel, oxaliplatin, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab)

pembrolizumab (Keytruda, KEYTRUDA(R, Pembrolizumab (KEYTRUDA(R)))

AIN457 (Secukinumab, Secukinumab (AIN457))

trastuzumab (Herceptin)

TMZ (Temozolomide, Temozolomide (TMZ))

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Tislelizumab (Tislelizumab)

Sintilimab (Sintilimab)

secukinumab (AIN457, AIN457 (secukinumab))

SG (Sacituzumab Govitecan-hziy, Sacituzumab Govitecan-hziy (SG))

Toripalimab (Toripalimab)

5-FU (Fluorouracil, Fluorouracil (5-FU))

Pegfilgrastim (Pegfilgrastim)

Palbociclib (Palbociclib)

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan (T-DXd) monotherapy)

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Regorafenib (Regorafenib)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Gemcitabine Hydrochloride (Gemcitabine Hydrochloride)

Ibrutinib (Ibrutinib)

Avelumab (Avelumab)

Luteinizing Hormone-Releasing Hormone (LHRH, Luteinizing Hormone-Releasing Hormone, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists)

Prednisolone (Prednisolone)

AK104 (Cadonilimab, Cadonilimab (AK104))

trastuzumab (Herceptin, FLOT, 5-FU, leucovorin, docetaxel, oxaliplatin, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab)

pembrolizumab (Keytruda, KEYTRUDA(R, Pembrolizumab (KEYTRUDA(R)))

AIN457 (Secukinumab, Secukinumab (AIN457))

trastuzumab (Herceptin)

TMZ (Temozolomide, Temozolomide (TMZ))

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Tislelizumab (Tislelizumab)

Sintilimab (Sintilimab)

secukinumab (AIN457, AIN457 (secukinumab))

SG (Sacituzumab Govitecan-hziy, Sacituzumab Govitecan-hziy (SG))

Toripalimab (Toripalimab)

5-FU (Fluorouracil, Fluorouracil (5-FU))

Pegfilgrastim (Pegfilgrastim)

Palbociclib (Palbociclib)

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan (T-DXd) monotherapy)

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Regorafenib (Regorafenib)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Gemcitabine Hydrochloride (Gemcitabine Hydrochloride)

Ibrutinib (Ibrutinib)

Avelumab (Avelumab)

Luteinizing Hormone-Releasing Hormone (LHRH, Luteinizing Hormone-Releasing Hormone, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists)

Prednisolone (Prednisolone)

AK104 (Cadonilimab, Cadonilimab (AK104))

trastuzumab (Herceptin, FLOT, 5-FU, leucovorin, docetaxel, oxaliplatin, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab)

pembrolizumab (Keytruda, KEYTRUDA(R, Pembrolizumab (KEYTRUDA(R)))

AIN457 (Secukinumab, Secukinumab (AIN457))

trastuzumab (Herceptin)

TMZ (Temozolomide, Temozolomide (TMZ))

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Tislelizumab (Tislelizumab)

Sintilimab (Sintilimab)